Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/2445/7303
dc.contributor | Universitat de Barcelona |
---|---|
dc.contributor.author | Carrió Díaz-Meco, Jaume |
dc.contributor.author | Portús Vinyeta, Montserrat |
dc.date | 2009-03-20T14:27:16Z |
dc.date | 2009-03-20T14:27:16Z |
dc.date | 2002 |
dc.identifier.citation | 1471-2210 |
dc.identifier.citation | 501553 |
dc.identifier.uri | http://hdl.handle.net/2445/7303 |
dc.format | 5 p. |
dc.format | application/pdf |
dc.language.iso | eng |
dc.publisher | BioMed Central |
dc.relation | Reproducció del document publicat a http://dx.doi.org/10.1186/1471-2210-2-11 |
dc.relation | BMC Pharmacology, 2002, vol. 2, núm. 11 |
dc.relation | http://dx.doi.org/10.1186/1471-2210-2-11 |
dc.rights | cc-by, (c) Carrió et al., 2002 |
dc.rights | info:eu-repo/semantics/openAccess |
dc.rights | http://creativecommons.org/licenses/by/2.0/ |
dc.subject | Resistència als medicaments |
dc.subject | Leishmaniosi |
dc.subject | Drug Resistance |
dc.subject | Leishmaniasis |
dc.title | In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/publishedVersion |
dc.description.abstract |